M. Müller

Psychopathological predictors of suicide in patients with major depression during a 5-year follow-up

Matthias J. Müller, B. Schneider, M. Philipp, 2001, European Psychiatry.

The MAOA T941G polymorphism and short‐term treatment response to mirtazapine and paroxetine in major depression

D. Rujescu, H. Stassen, N. Dahmen, 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

Fluvoxamine But Not Sertraline Inhibits the Metabolism of Olanzapine: Evidence From A Therapeutic Drug Monitoring Service

C. Hiemke, S. Härtter, H. Weigmann, 2001, Therapeutic drug monitoring.

Frequency and dependence on body posture of hallucinations and sleep paralysis in a community sample

N. Dahmen, M. Kasten, K. Mittag, 2002, Journal of sleep research.

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

C. Hiemke, S. Härtter, M J Müller, 2006, Journal of clinical pharmacy and therapeutics.

Catecholamine Response Curves of Male Hypertensives Identified by Lehmacher's Two Sample Configural Frequency Analysis

A. von Eye, P. Netter, M. Müller, 1997 .

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

R Kohnen, D. Rujescu, H. Stassen, 2005, The Pharmacogenomics Journal.

Improvement of inter‐rater reliability of PANSS items and subscales by a standardized rater training

H. Wetzel, M. Müller, M. Müller, 1998, Acta psychiatrica Scandinavica.

Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.

Michael Grözinger, Matthias J. Müller, M. Grözinger, 2003, Pharmacopsychiatry.

Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale.

A. Szegedi, H. Wetzel, O. Benkert, 2000, Journal of affective disorders.

The Serotonin Transporter Promoter Polymorphism (5-HTTLPR) Affects the Relation between Antidepressant Serum Concentrations and Effectiveness in Major Depression

M. Rietschel, J. Röschke, B. Bondy, 2011, Pharmacopsychiatry.

Therapeutic Drug Monitoring of Tricyclic Antidepressants: How Does it Work under Clinical Conditions?

G. Laux, M. Fric, C. Hiemke, 2003, Pharmacopsychiatry.

An overview of the clinical efficacy of mirtazapine

A. Szegedi, O. Benkert, M. Müller, 2002, Human psychopharmacology.

Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms.

J. Röschke, K. Mann, H. Wetzel, 2004, Pharmacopsychiatry.